Skip to main content

 3LCO | pdb_00003lco

Inhibitor Bound to A DFG-Out structure of the Kinase Domain of CSF-1R


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 3.40 Å
  • R-Value Free: 
    0.289 (Depositor), 0.273 (DCC) 
  • R-Value Work: 
    0.245 (Depositor), 0.242 (DCC) 
  • R-Value Observed: 
    0.247 (Depositor) 

wwPDB Validation 3D Report Full Report

Validation slider image for 3LCO

Ligand Structure Quality Assessment 


This is version 1.3 of the entry. See complete history. 

Literature

Structure-based drug design enables conversion of a DFG-in binding CSF-1R kinase inhibitor to a DFG-out binding mode.

Meyers, M.J., Pelc, M., Kamtekar, S., Day, J., Poda, G.I., Hall, M.K., Michener, M.L., Reitz, B.A., Mathis, K.J., Pierce, B.S., Parikh, M.D., Mischke, D.A., Long, S.A., Parlow, J.J., Anderson, D.R., Thorarensen, A.

(2010) Bioorg Med Chem Lett 20: 1543-1547

  • DOI: https://doi.org/10.1016/j.bmcl.2010.01.078
  • Primary Citation Related Structures: 
    3LCD, 3LCO

  • PubMed Abstract: 

    The work described herein demonstrates the utility of structure-based drug design (SBDD) in shifting the binding mode of an HTS hit from a DFG-in to a DFG-out binding mode resulting in a class of novel potent CSF-1R kinase inhibitors suitable for lead development.


  • Organizational Affiliation: 
    • Pfizer Global Research & Development, St. Louis Laboratories, 700 Chesterfield Parkway West, Chesterfield, MO 63017, United States. marvin.j.meyers@pfizer.com

Macromolecule Content 

  • Total Structure Weight: 36.73 kDa 
  • Atom Count: 2,288 
  • Modeled Residue Count: 293 
  • Deposited Residue Count: 324 
  • Unique protein chains: 1

Macromolecules

Find similar proteins by:|  3D Structure
Entity ID: 1
MoleculeChains  Sequence LengthOrganismDetailsImage
Macrophage colony-stimulating factor 1 receptor324Homo sapiensMutation(s): 0 
Gene Names: CSF-1R, CSF1R, FMS
EC: 2.7.10.1
UniProt & NIH Common Fund Data Resources
Find proteins for P07333 (Homo sapiens)
Explore P07333 
Go to UniProtKB:  P07333
PHAROS:  P07333
GTEx:  ENSG00000182578 
Entity Groups
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupP07333
Sequence Annotations
Expand
Reference Sequence

Small Molecules

Ligands 1 Unique
IDChains Name / Formula / InChI Key2D Diagram3D Interactions
LC0

Query on LC0



Download:Ideal Coordinates CCD File
B [auth A]3-({4-methoxy-5-[(4-methoxybenzyl)oxy]pyridin-2-yl}methoxy)-5-(1-methyl-1H-pyrazol-4-yl)pyrazin-2-amine
C23 H24 N6 O4
FYNJLBSSIPLISK-UHFFFAOYSA-N

Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 3.40 Å
  • R-Value Free:  0.289 (Depositor), 0.273 (DCC) 
  • R-Value Work:  0.245 (Depositor), 0.242 (DCC) 
  • R-Value Observed: 0.247 (Depositor) 
Space Group: P 43 21 2
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 62.916α = 90
b = 62.916β = 90
c = 183.943γ = 90
Software Package:
Software NamePurpose
HKL-2000data collection
REFMACrefinement
HKL-2000data reduction
HKL-2000data scaling
REFMACphasing

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment 


Entry History 

Deposition Data

Revision History  (Full details and data files)

  • Version 1.0: 2010-09-15
    Type: Initial release
  • Version 1.1: 2011-07-13
    Changes: Version format compliance
  • Version 1.2: 2017-08-16
    Changes: Refinement description, Source and taxonomy
  • Version 1.3: 2024-02-21
    Changes: Data collection, Database references, Derived calculations